|
Carving
a new path
As Indian pharmaceutical companies find themselves blocked
by rising API prices, many are finding ways to circumvent
the obstacles. Arshiya Khan explores
DRL-Albemarle
distribution tie up for Ibuprofen API
Dr Reddy's Laboratories (DRL) has signed a global distribution
agreement for Ibuprofen Active Pharmaceutical Ingredient (API)
with a US-based specialty chemicals company, Albemarle Corporation.
Veeda
Oncology acquires ION's US clinical research group
Veeda Clinical Research's group company Veeda Oncology has
acquired the clinical research group of the US based International
Oncology Network (ION) Clinical Research Organisation (CRO).
CREMA
to set up three centres in metros
A premier training institute for clinical research industry,
CREMA (Clinical Research Education and Management Academy)
is investing Rs 15 crore for setting up three more institutes
in Hyderabad, Kolkota and Ahmedabad.
Glenmark
to sell derma products in Poland by December
As part of its continuous global expansion plans, Glenmark
Pharmaceuticals will launch dermatology products by the end
of current calendar year in the Poland market.
Panacea
plans a multi super-specialty hospital in Gurgaon
Panacea Biotec is expanding its portfolio by entering the
fast growing healthcare delivery sector. Recently, it has
entered into collaboration with Dr Umesh Gupta of Umkal Group
for setting-up a 220 bed multi super-specialty with the most
modern equipment in the National Capital Region of Delhi at
Gurgaon.
IFC
to invest $15 million in Hikal
Hikal, global life sciences company announced that International
Finance Corporation (IFC), a member of the World Bank group,
has agreed to invest $15 million in Hikal by way of equity
participation.
Suven
to present SUVN-502 at ICAD-2008 in Chicago
Suven Life Sciences, will present the portfolio of investigational
neuroscience new chemical entities (NCEs) at Alzheimer's conference
(ICAD) to be held at Chicago USA from July 27 to 31, 2008.
Lupin
inks marketing pact with ASCEND therapeutics
Lupin has entered into a promotion agreement with ASCEND Therapeutics,
for Suprax 400 mg tablets. Under the terms of the alliance,
ASCEND has already commenced promotion of the product in US
from June 2008.
Plethico
plans to trim CRAMS business
Plethico Pharmaceuticals is planning for trimming its Contract
Research and Manufacturing Services (CRAMS) business, as low
margins are being further squeezed due to higher inflation
and surging crude oil prices.
Bafna
Pharmaceuticals listed on BSE
Bafna Pharmaceuticals (Bafna), a multi-product pharmaceutical
formulations company in diverse therapeutic segments was recently
listed on BSE at Rs 43.80, as against its offer price of Rs
40 per share, at a premium of 9.50 percent. The scrip closed
at Rs 38.50 on the BSE.
Sun
Pharmaceutical exercises its options
Sun Pharmaceutical Industries' subsidiary has exercised the
option under its option agreement to acquire all the shares
held by the controlling shareholders of Taro Pharmaceuticals
Industries (Taro).
Nestor
Pharma plans super speciality division
Nestor Pharmaceuticals is planning to launch a super-speciality
division, by the name Long-term Therapy Division (LTD). This
division is expected to cater to the needs of the doctors
to treat diabetic, cardiac and neuro psychotropic patients.
Preparations
for 60th IPC progress at full speed
The Local Organising Committee (LOC) of the 60th Indian Pharmaceutical
Congress (IPC) 2008, met for the third time on June 28, to
brainstorm over the selection of an appropriate logo.
CMP
India launches CPhI/P-MEC/ ICSE India 2008
South Asia's pharmaceutical industry gets three comprehensive
events encompassing ingredients, machinery and technology,
and contract manufacturing
Event
Briefs
Collaborating
for research technology through PPP
Since the Indian Government recognised the usefulness of public
private partnerships (PPPs) as a tool to promote innovation
and entrepreneurship, there has been lot happening in the
pharmaceutical industry. The Public Private Partnership summit
2008 provided a platform for discussions on the scope and
future of PPPs. Aashruti Kak and Suja Nair report
|
